• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

未经治疗的非手术性肝细胞癌的自然病史。

Natural history of untreated nonsurgical hepatocellular carcinoma.

作者信息

Yeung Yuk Pang, Lo Chung Mau, Liu Chi Leung, Wong Benjamin C, Fan Sheung Tat, Wong John

机构信息

Department of Surgery, Kwong Wah Hospital, and Centre for the Study of Liver Disease, China.

出版信息

Am J Gastroenterol. 2005 Sep;100(9):1995-2004. doi: 10.1111/j.1572-0241.2005.00229.x.

DOI:10.1111/j.1572-0241.2005.00229.x
PMID:16128944
Abstract

OBJECTIVE

Hepatocellular carcinoma (HCC) is common in Asia, and the majority are not suitable for curative surgical treatment. We studied the natural history of untreated nonsurgical HCC to examine whether the prognosis has changed with improved supportive treatment and to identify factors affecting survival.

METHODS

One hundred and six ethnic Chinese patients with HCC not amenable to curative treatment were managed symptomatically as control-arm patients in three randomized studies conducted between January 1996 and April 2001. Seventy-six (71.7%) patients were positive for hepatitis B surface antigen (HBsAg). Prognostic variables for survival were identified by univariate analysis and were subjected to a multivariate Cox analysis to identify the independent predictors of survival.

RESULTS

All but four patients were followed until death. Common causes of death were tumor progression (63.2%) and liver failure (31.1%). The overall median survival was 3 months, and the 1-yr survival was 7.8% only. The median survival of patients of Okuda stages I, II, and III were 5.1 months, 2.7 months, and 1.0 month, respectively (p < 0.05 for comparison between any two stages). Multivariate analysis revealed four independent prognostic variables, namely, serum bilirubin, blood urea, serum alpha-fetoprotein, and Okuda stage.

CONCLUSIONS

The prognosis of untreated HCC not suitable for curative treatment in Asia is grave despite improved supportive treatment. The four prognostic variables identified in this study are important in the decision for palliative treatment, and the Okuda staging remains an important prognostic guide.

摘要

目的

肝细胞癌(HCC)在亚洲较为常见,且大多数患者不适合进行根治性手术治疗。我们研究了未经治疗的非手术HCC的自然病程,以探讨随着支持治疗的改善预后是否发生了变化,并确定影响生存的因素。

方法

1996年1月至2001年4月期间进行的三项随机研究中,106例不适合进行根治性治疗的华裔HCC患者作为对照臂患者接受了对症治疗。76例(71.7%)患者乙肝表面抗原(HBsAg)呈阳性。通过单因素分析确定生存的预后变量,并进行多因素Cox分析以确定生存的独立预测因素。

结果

除4例患者外,所有患者均随访至死亡。常见死亡原因是肿瘤进展(63.2%)和肝衰竭(31.1%)。总体中位生存期为3个月,1年生存率仅为7.8%。奥田分期I、II和III期患者的中位生存期分别为5.1个月、2.7个月和1.0个月(任意两个分期之间比较,p<0.05)。多因素分析显示四个独立的预后变量,即血清胆红素、血尿素、血清甲胎蛋白和奥田分期。

结论

尽管支持治疗有所改善,但亚洲不适合进行根治性治疗的未经治疗的HCC预后仍然很差。本研究确定的四个预后变量在姑息治疗决策中很重要,奥田分期仍然是重要的预后指导。

相似文献

1
Natural history of untreated nonsurgical hepatocellular carcinoma.未经治疗的非手术性肝细胞癌的自然病史。
Am J Gastroenterol. 2005 Sep;100(9):1995-2004. doi: 10.1111/j.1572-0241.2005.00229.x.
2
Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.接受非手术治疗的早中期肝细胞癌患者生存的预后因素:意大利单一中心对奥田、CLIP和BCLC分期系统的比较
Gut. 2005 Mar;54(3):411-8. doi: 10.1136/gut.2004.048124.
3
Treatment and prognostic factors in patients with hepatocellular carcinoma.肝细胞癌患者的治疗及预后因素
Liver Int. 2006 Aug;26(6):680-7. doi: 10.1111/j.1478-3231.2006.001285.x.
4
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.未经治疗的非手术性肝细胞癌的自然病史:治疗试验设计与评估的基本原理
Hepatology. 1999 Jan;29(1):62-7. doi: 10.1002/hep.510290145.
5
Predictors of long-term survival after liver transplantation for hepatocellular carcinoma.肝细胞癌肝移植术后长期生存的预测因素。
Am J Gastroenterol. 2005 Dec;100(12):2708-16. doi: 10.1111/j.1572-0241.2005.00289.x.
6
Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma.2002年美国癌症联合委员会第6版分期系统对可切除肝细胞癌患者的预后价值及临床意义
J Am Coll Surg. 2006 Oct;203(4):426-35. doi: 10.1016/j.jamcollsurg.2006.06.030. Epub 2006 Aug 23.
7
Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong.香港肝细胞癌患者的临床特征、生化参数及病毒学特征
Aliment Pharmacol Ther. 2006 Aug 15;24(4):573-83. doi: 10.1111/j.1365-2036.2006.03029.x.
8
Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response.在一组接受射频消融且完全缓解的肝硬化肝细胞癌患者中,对七种分期系统的比较。
Am J Gastroenterol. 2008 Mar;103(3):597-604. doi: 10.1111/j.1572-0241.2007.01604.x. Epub 2007 Oct 26.
9
Serum C-reactive protein levels predict survival in hepatocellular carcinoma.血清C反应蛋白水平可预测肝细胞癌患者的生存率。
Liver Int. 2007 Oct;27(8):1091-7. doi: 10.1111/j.1478-3231.2007.01550.x.
10
Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.甲胎蛋白及维生素K缺乏或拮抗剂-II诱导蛋白在乙型肝炎病毒相关肝细胞癌中的预后价值:一项前瞻性研究
J Clin Gastroenterol. 2009 May-Jun;43(5):482-8. doi: 10.1097/MCG.0b013e318182015a.

引用本文的文献

1
Establishment of a prognosis-related predictive model for hepatocellular carcinoma patients with macrovascular invasion treated with transcatheter arterial chemoembolization combined with intensity modulated radiotherapy.建立经动脉化疗栓塞联合调强放疗治疗的伴有大血管侵犯的肝细胞癌患者的预后相关预测模型。
Transl Cancer Res. 2025 Feb 28;14(2):1214-1222. doi: 10.21037/tcr-24-1226. Epub 2025 Feb 24.
2
Integrated analysis reveals an immune evasion prognostic signature for predicting the overall survival in patients with hepatocellular carcinoma.综合分析揭示了一种免疫逃逸预后特征,用于预测肝细胞癌患者的总生存期。
Cancer Cell Int. 2025 Mar 18;25(1):101. doi: 10.1186/s12935-025-03743-9.
3
Single-cell and bulk transcriptomic datasets enable the development of prognostic models based on dynamic changes in the tumor immune microenvironment in patients with hepatocellular carcinoma and portal vein tumor thrombus.
单细胞和批量转录组数据集使基于肝癌和门静脉癌栓患者肿瘤免疫微环境动态变化的预后模型的开发成为可能。
Front Immunol. 2024 Oct 28;15:1414121. doi: 10.3389/fimmu.2024.1414121. eCollection 2024.
4
Challenges and Suggestions in Management of Lung and Liver Cancer in Uzbekistan: The Second Report of the Uzbekistan-Korea Oncology Consortium.乌兹别克斯坦肺癌和肝癌管理的挑战和建议:乌兹别克斯坦-韩国肿瘤学联盟的第二次报告。
Int J Environ Res Public Health. 2022 Sep 17;19(18):11727. doi: 10.3390/ijerph191811727.
5
Will the collaboration of surgery and external radiotherapy open new avenues for hepatocellular carcinoma with portal vein thrombosis?手术与外照射放疗的联合应用会为伴有门静脉血栓形成的肝细胞癌开辟新的治疗途径吗?
World J Gastroenterol. 2022 Feb 21;28(7):704-714. doi: 10.3748/wjg.v28.i7.704.
6
Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy.病例报告:全身治疗后晚期肝细胞癌转化手术治疗效果延迟一年
Front Mol Biosci. 2022 Feb 4;8:810251. doi: 10.3389/fmolb.2021.810251. eCollection 2021.
7
Hepatocellular Carcinoma (HCC) in North-Western India: A Retrospective Study Focusing on Epidemiology, Risk Factors, and Survival.印度西北部的肝细胞癌:一项聚焦于流行病学、危险因素和生存情况的回顾性研究
J Gastrointest Cancer. 2022 Dec;53(4):921-929. doi: 10.1007/s12029-021-00712-z. Epub 2021 Sep 22.
8
Distant survival for patients undergoing surgery using volatile versus IV anesthesia for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.接受挥发性麻醉与静脉麻醉的肝细胞癌合并门静脉癌栓患者的手术治疗:一项回顾性研究。
BMC Anesthesiol. 2020 Sep 14;20(1):233. doi: 10.1186/s12871-020-01111-w.
9
Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization.立体定向消融放疗对不适用于经动脉化疗栓塞的晚期肝细胞癌患者的疗效
Ther Adv Med Oncol. 2019 Dec 4;11:1758835919889002. doi: 10.1177/1758835919889002. eCollection 2019.
10
Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma.丙型肝炎病毒基因型影响肝癌患者的生存。
BMC Cancer. 2019 Aug 20;19(1):822. doi: 10.1186/s12885-019-6040-3.